Evaluating Serum Sestrin in Leiomyoma Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

61 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-01-01

Study Completion Date

2021-04-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Leiomyomas are the most common benign neoplasms of women's reproductive system affecting 20-30% of women within the reproductive ages. Sestrins are serum proteins which are highly expressed under circumstances of DNA damage, hypoxia and oxditive stress and play an important role in autophagia. The aim of this study is to evaluate the relationship of serum sestrin proteins with development of leiomyomas.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Epidemiology and Risk Factors of Uterine Fibroids in China

NCT05840042

Uterine Fibroid

NOT_YET_RECRUITING

Establishment of a Decision Aid Tool for Asymptomatic Small Leiomyoma and Analysis of Influencing Factors for Clinical Decision-making Using HIFU

NCT05500118

Leiomyoma, Uterine High-Intensity Focused Ultrasound Ablation Patients Decision Aids

RECRUITING

Progesterone Induced Blocking Factor Expression Levels in Endometrial Cancer Cells.

NCT02852954

Progesterone Induced Blocking Factor in Endometrial Cancer

COMPLETED

The Clinical Trial About Treatment of Benign Uterus Myoma by Haifu Focused Ultrasound Tumor Therapeutic System

NCT05569200

Benign Uterine Tumor

UNKNOWN NA

A Prospective Validation Study of Radiomics in the Differential Diagnosis of Uterine Leiomyoma and Uterine Sarcoma

NCT07269535

Uterine Fibroid Uterine Sarcoma AI (Artificial Intelligence) +3 more

NOT_YET_RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Leiomyomas are the benign neoplasms of uterus and the role of genetics, estrogen levels and obesity has already been shown in their development. Higher levels of serum sestrin proteins have already been associated with DNA damage, hypoxia and oxidative stress and sestrin plays an important role in autophagia. In order to evaluate the role of serum sestrin in the development of leiomyomas 30 patients between 18-45 years of age who were diagnosed with uterine leiomyomas with transvaginal ultrasonography will be included in the study group. Their serum sestrin levels will be determined and compared with that of 30 healthy subjects recruited during the same study period at the same clinic.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Uterine Leiomyoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Study Group

30 patients within the reproductive ages (18-45 years) who were diagnosed with leiomyomas using transvaginal ultrasonography without any additional chronic, systemic or autoimmune disease, are not currently using any medical, hormonal, antiinflammatory treatments are included in this group.

Determination of serum sestrin levels

Intervention Type OTHER

Serum sestrin levels will be determined using venous blood samples obtained from the subjects.

Control Group

30 healthy subjects within the reproductive ages (18-45 years) who visited the outpatient gynecological clinic for routine examination who do not have any additional chronic, systemic or autoimmune disease, who are not currently using any medical, hormonal, antiinflammatory treatments are included in this group.

Determination of serum sestrin levels

Intervention Type OTHER

Serum sestrin levels will be determined using venous blood samples obtained from the subjects.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Determination of serum sestrin levels

Serum sestrin levels will be determined using venous blood samples obtained from the subjects.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 18-45 years of age
* patients diagnosed with uterine leiomyomas will be included in the study group
* patients without any additional comorbidities
* patients without any autoimmune diseases

Exclusion Criteria

* patients with systemic diseases
* patients with known chronic inflammatory diseases
* patients using hormonal and/or medical therapy
* pregnant women
* lactating women
* patients with malignant diseases

Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes